Axamon® (Axamon®)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceIpidacrinIpidacrin
Similar drugsTo uncover
  • Axamon®
    solution w / m PC 
    PIK-PHARMA, LLC     Russia
  • Axamon®
    pills inwards 
    PIK-PHARMA, LLC     Russia
  • Ipigrix®
    solution w / m PC 
    GRINDEX, JSC     Latvia
  • Ipigrix®
    pills inwards 
    GRINDEX, JSC     Latvia
  • Neuromidine®
    pills inwards 
    Olainfarm, AO     Latvia
  • Neuromidine®
    solution w / m PC 
    Olainfarm, AO     Latvia
    • Dosage form: & nbsppills
    Composition:1 tablet contains:

    active substance: ipidacrine hydrochloride monohydrate 21.6 mg (corresponding to 20 mg ipidacrine hydrochloride);

    Excipients: ludistress (lactose monohydrate from 91 to 95%, Kollidon 30 (povidone) from 3.0 to 4.0%, Kollidon CL (crospovidone) 3.0 to 4.0%) 63.4 mg, sodium carboxymethyl starch 14 mg, calcium stearate 1 mg.

    Description:

    Tablets are white in color, round in shape, flat-cylindrical, with a bevel.

    Pharmacotherapeutic group:Cholinesterase inhibitor
    ATX: & nbsp

    N.07.A.A   Anticholinesterase drugs

    Pharmacodynamics:

    Reversible cholinesterase inhibitor. Due to blockade of potassium channels of cell membranes and inhibition of cholinesterase activity, it stimulates neuromuscular transmission and conduction of impulses in the nervous system. Has M- and H-cholinomimetic action. Strengthens the effect of acetylcholine, serotonin, histamine and oxytocin on smooth muscles, as a result of which increases the contractility of smooth muscle organs, incl.GASTROINTESTINAL TRACT and bronchial tubes, reduces heart rate, increases secretion of salivary glands, contractile activity of myometrium, tone of skeletal musculature. Has a stimulating effect on the central nervous system in combination with individual manifestations of sedation; improves learning and memory.

    Pharmacokinetics:

    Quickly absorbed from the gastrointestinal tract. The maximum concentration in the blood plasma is reached after one hour. 40-55% of the active substance binds to blood plasma proteins. The half-life is about 40 minutes. Metabolised in the liver. Excretion is carried out through the kidneys (mainly by tubular secretion and only 1/3 of the drug is secreted by glomerular filtration), and also extrarenally (through the gastrointestinal tract).

    Indications:

    - Diseases of the peripheral nervous system (neuritis, polyneuritis and polyneuropathy, polyradiculopathies, myasthenia gravis and myasthenic syndrome of various etiologies);

    - the recovery period of organic lesions of the central nervous system, accompanied by motor disorders, including bulbar paralysis and paresis;

    - complex therapy of demyelinating diseases;

    - senile dementia, Alzheimer's disease, encephalopathy of various genesis.

    Contraindications:

    Hypersensitivity to any component of the drug, epilepsy, extrapyramidal disorders with hyperkinesis, angina pectoris, bradycardia, bronchial asthma, mechanical bowel obstruction or urinary tract, vestibular disorders, gastric ulcer or duodenal ulcer in the acute stage, galactose intolerance, lactase deficiency or of glucose galactose malabsorption, pregnancy and lactation, children under 18 years.

    Carefully:

    In gastric ulcer and duodenal ulcer in remission, thyrotoxicosis, intracardiac conduction disorders, obstructive diseases of the respiratory system or a history of acute respiratory diseases.

    Dosing and Administration:

    Inside. Doses and duration of treatment are determined individually, depending on the severity of the disease.

    Diseases of the peripheral nervous system, myasthenia gravis, myasthenic syndrome: 10-20 mg 1-3 times a day. The course of treatment is from one to two months.If necessary, the course of treatment can be repeated several times with a break between courses in 1-2 months.

    Alzheimer's disease, encephalopathy, the recovery period of organic diseases of the central nervous system, accompanied by motor disorders, including bulbar paralysis and paresis: the daily dose is selected individually, usually 10-20 mg 2-3 times a day.

    With demyelinating lesions of the nervous system the dose can be increased to 20-40 mg 5-6 times a day.

    The maximum daily dose is 200 mg.

    If one of the techniques was missed, the next dose is taken as a usual dose of the drug.

    Side effects:

    Caused by excitation of m-cholinergic receptors: salivation, increased sweating, nausea, diarrhea, jaundice, bradycardia, epigastric pain, increased secretion of bronchial secretions, bronchospasm, convulsions, increased uterus tone. Salivation and bradycardia can be reduced by m-holinoblokatorami: atropine, trihexyphenidyl (cyclodol), metocinium iodide (metacin), and others.

    Less often, after using higher doses, dizziness, ataxia, headache, vomiting, general weakness, drowsiness, skin reactions (pruritus, rash) were observed.In these cases, reduce the dose or briefly (for 1-2 days) interrupt the reception of the drug.

    Overdose:

    Symptoms: decreased appetite, bronchospasm, lacrimation, sweating, pupillary constriction, nystagmus, increasing motility of the gastrointestinal tract, spontaneous defecation and urination, vomiting, jaundice, bradycardia, impaired intracardiac conduction, arrhythmias, blood pressure, anxiety, worry, agitation, a feeling fear, ataxia, convulsions, coma, speech disorders, drowsiness and general weakness.

    Treatment: gastric lavage, use of m-holinoblokatorov (atropine, trihexyphenidyl (cyclodol), metocinium iodide (metacin), etc.), symptomatic therapy.

    Interaction:

    Enhances sedation in combination with drugs that depress the central nervous system.

    Effects and side effects are enhanced when combined with other cholinesterase inhibitors and m-cholinomimetic agents.

    In patients with myasthenia gravis, the risk of developing a cholinergic crisis increases, if you apply ipidacrin simultaneously with other cholinergic agents.

    The risk of developing a bradycardia increases, if β-blockers were used before the start of treatment.

    Relieves the depressing effect on neuromuscular transmission and conduction of excitation along the peripheral nerves of local anesthetics, aminoglycosides, potassium chloride.

    Alcohol increases the side effects of the drug.

    Effect on the ability to drive transp. cf. and fur:

    During treatment should refrain from driving the car, as well as practicing potentially dangerous activities that require increased concentration and speed of psychomotor reactions.

    Form release / dosage:

    Tablets of 20 mg.

    Packaging:

    10 tablets per contour cell pack.

    5 contour mesh packages together with the instruction for use are placed in a pack of cardboard.

    Storage conditions:In a dry, the dark place at a temperature of no higher than 25 ° C.
    Keep out of the reach of children.
    Shelf life:3 years.
    Do not use after the expiration date printed on the package.
    Terms of leave from pharmacies:On prescription
    Registration number:P N003550 / 01
    Date of registration:25.09.2009 / 12.08.2014
    Expiration Date:Unlimited
    The owner of the registration certificate:PIK-PHARMA, LLC PIK-PHARMA, LLC Russia
    Manufacturer: & nbsp
    Representation: & nbspPIK-PHARMA LLC PIK-PHARMA LLC Russia
    Information update date: & nbsp03.07.2017
    Illustrated instructions
      Instructions
      Up